Literature DB >> 15693648

PET imaging in the assessment of normal and impaired cognitive function.

Daniel H S Silverman1, Abass Alavi.   

Abstract

PET has been used to directly quantify several processes relevant to the status of cerebral health and function, including cerebral blood flow, cerebral blood volume, cerebral rate of oxygen metabolism, and cerebral glucose use. Clinically, the most commonly performed PET studies of the brain are performed with fluorine-18-fluorodeoxyglucose as the imaged radiopharmaceutical. Such scans have demonstrated diagnostic and prognostic use in evaluating patients who have cognitive impairment, and in distinguishing among primary neurodegenerative dementias and other causes of cognitive decline. In certain pathologic circumstances, the normal coupling between blood flow and metabolic needs may be disturbed, and changes in oxygen extraction fraction can have significant prognostic value.

Entities:  

Mesh:

Year:  2005        PMID: 15693648     DOI: 10.1016/j.rcl.2004.09.012

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  17 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 2.  Positron emission tomography scans obtained for the evaluation of cognitive dysfunction.

Authors:  Daniel H S Silverman; Lisa Mosconi; Linda Ercoli; Wei Chen; Gary W Small
Journal:  Semin Nucl Med       Date:  2008-07       Impact factor: 4.446

3.  Joint correction of attenuation and scatter in image space using deep convolutional neural networks for dedicated brain 18F-FDG PET.

Authors:  Jaewon Yang; Dookun Park; Grant T Gullberg; Youngho Seo
Journal:  Phys Med Biol       Date:  2019-04-04       Impact factor: 3.609

Review 4.  Clinical 18F-FDG and amyloid brain positron emission tomography/CT in the investigation of cognitive impairment: where are we now?

Authors:  Maureen Dumba; Sairah Khan; Neva Patel; Laura Perry; Paresh Malhotra; Richard Perry; Kuldip Nijran; Tara Barwick; Kathryn Wallitt; Zarni Win
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

5.  Blood flow magnetic resonance imaging of retinal degeneration.

Authors:  Yingxia Li; Haiying Cheng; Qiang Shen; Moon Kim; Peter M Thule; Darin E Olson; Machelle T Pardue; Timothy Q Duong
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

6.  Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

Authors:  Ann D Cohen; Julie C Price; Lisa A Weissfeld; Jeffrey James; Bedda L Rosario; Wenzhu Bi; Robert D Nebes; Judith A Saxton; Beth E Snitz; Howard A Aizenstein; David A Wolk; Steven T Dekosky; Chester A Mathis; William E Klunk
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

Review 7.  Early detection of Alzheimer's disease using PiB and FDG PET.

Authors:  Ann D Cohen; William E Klunk
Journal:  Neurobiol Dis       Date:  2014-05-10       Impact factor: 5.996

8.  Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy.

Authors:  Helene Benveniste; Shaonan Zhang; Ruth A Reinsel; Haifang Li; Hedok Lee; Mario Rebecchi; William Moore; Christoffer Johansen; Douglas L Rothman; Thomas V Bilfinger
Journal:  Int J Clin Exp Med       Date:  2012-04-06

9.  Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.

Authors:  Kun-Ju Lin; Ing-Tsung Hsiao; Jung-Lung Hsu; Chin-Chang Huang; Kuo-Lun Huang; Chia-Ju Hsieh; Shiaw-Pyng Wey; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-22       Impact factor: 9.236

Review 10.  Neuroimaging, cancer, and cognition: state of the knowledge.

Authors:  Kelly N Holohan; Diane Von Ah; Brenna C McDonald; Andrew J Saykin
Journal:  Semin Oncol Nurs       Date:  2013-11       Impact factor: 2.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.